Abatacept therapy and safety management

Joint Bone Spine

Volumn 79, Issue SUPPL. 1, 2012, Pages 3-84

  Pham, Thao ^a   Bachelez, Hervé ^b   Berthelot, Jean Marie ^c   Blacher, Jacques ^d   Claudepierre, Pascal ^e   Constantin, Arnaud ^f   Fautrel, Bruno ^g   Gaujoux Viala, Cécile ^g   Goëb, Vincent ^h   Gossec, Laure ⁱ   Goupille, Philippe ^j   Guillaume Czitrom, Séverine ^k   Hachulla, Eric ^l   Lequerré, Thierry ^h   Marolleau, Jean Pierre ^m   Martinez, Valérie ⁿ   Masson, Charles ^o   Mouthon, Luc ⁱ   Puéchal, Xavier ^p   Richette, Pascal ^q   Saraux, Alain ^r   Schaeverbeke, Thierry ^s   Soubrier, Martin ^t   Viguier, Manuelle ^b   Vittecoq, Olivier ^h   Wendling, Daniel ^u   Mariette, Xavier ^k   Sibilia, Jean ^v   more..

^a HÔPITAL SAINTE MARGUERITE   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c HÔTEL DIEU   (France)

^d HÔTEL DIEU   (France)

^e HENRI MONDOR HOSPITAL   (France)

^f CHU PURPAN   (France)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h ROUEN UNIVERSITY HOSPITAL   (France)

ⁱ CHU Trousseau ^*  (France)

^j SERVICE DE DERMATOLOGIE   (France)

^k BICÊTRE HOSPITAL   (France)

^l LILLE UNIVERSITY HOSPITAL   (France)

^m AMIENS UNIVERSITY HOSPITAL   (France)

ⁿ HÔPITAL ANTOINE BÉCLÈRE   (France)

^o ANGERS UNIVERSITY HOSPITAL   (France)

^p CENTRE HOSPITALIER DU MANS   (France)

^q HÔPITAL LARIBOISIÈRE   (France)

^r SERVICE DE RHUMATOLOGIE   (France)

^s HÔPITAL PELLEGRIN   (France)

^t SERVICE DE RHUMATOLOGIE   (France)

^u UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^v HÔPITAL DE HAUTEPIERRE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; AZATHIOPRINE; GOLD; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE;

ACUTE INFUSION REACTION; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIBODY PRODUCTION; ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; BACTERIAL MENINGITIS; BACTERIURIA; BENIGN TUMOR; CHICKENPOX; CONNECTIVE TISSUE DISEASE; CONSENSUS DEVELOPMENT; DENGUE; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ERYSIPELAS; EVIDENCE BASED MEDICINE; GASTROENTERITIS; HERPES ZOSTER; HERPES ZOSTER ENCEPHALITIS; HUMAN; INFECTION; INFLUENZA; INFORMATION DISSEMINATION; INJECTION SITE REACTION; JUVENILE RHEUMATOID ARTHRITIS; LUNG CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE SCLEROSIS; MUSCLE DISEASE; NONHUMAN; PATIENT INFORMATION; PATIENT MONITORING; PRACTICE GUIDELINE; PSORIASIS; PSORIATIC ARTHRITIS; PYELONEPHRITIS; RHEUMATOID ARTHRITIS; RHINITIS; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SJOEGREN SYNDROME; SKIN CANCER; SOLID TUMOR; SPONDYLOARTHROPATHY; SYSTEMATIC REVIEW; UPPER RESPIRATORY TRACT INFECTION; UVEITIS; VASCULITIS;

ANTIRHEUMATIC AGENTS; COMORBIDITY; DISEASE MANAGEMENT; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOCONJUGATES; PRACTICE GUIDELINES AS TOPIC; RHEUMATIC DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84860252733     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/S1297-319X(12)70011-8     Document Type: Article

References (128)

1. Kremer J.M., Westhovens R., Le Bars M., et al. Time to treatment response with abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Rheum 2008, 58(Suppl 9):378.
2. Schiff M., Dougados M., Le Bars M., et al. Time to treatment response with abatacept in patients with RA and an inadequate response to anti-TNF therapy. Arthritis Rheum 2008, 58(Suppl 9):377.
3. Genovese M., Becker J.C., Schiff M., et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor inhibition. N Engl J Med 2005, 353:1114-1123.
4. Hochberg M., Westhovens R., Aranda R., et al. Long-term safety of abatacept: integrated analysis of clinical program data of up to 7 years of treatment. Arthritis Rheum 2010, 62(Suppl 10):S142.
5. EMA - Scientific discussion for Orencia - London, 21 May 2010.
6. Peters M.J.L., Symmons D.P.M., McCarey D., et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010, 69:325-331.
7. Pham T., Bachelez H., Berthelot J.-M., et al. TNF alpha antagonist therapy and safety monitoring. Joint Bone Spine 2011, 78(Suppl1):S15-S185.
8. Saag K.G., Teng G.G., Patkar N.M., et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008, 59:762-784.
9. Nam J.L., Winthrop K.L., van Vollenhoven R.F., et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 2010, 69:976-986.
10. Cesco-Gaspere M., Morris E., Stauss H. Immunomodulation in the treatment of haematological malignancies. Clin Exp Med 2009, 9:81-92.
11. Ansell S., Hurvitz S., Koenig P., Phase I., et al. Study of Ipilimumab, an Anti-CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma. Clin Cancer Res 2009, 15:6446-6453.
12. Callahan M., Wolchok J., Allison J. Anti-CTLA-4 Antibody Therapy: Immune Monitoring During Clinical Development of a Novel Immunotherapy. Semin Oncol 2010, 37:473-484.
13. Simon T., Smitten A., Franklin J., et al. Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment. Ann Rheum Dis 2009, 68:1819-1826.
14. Becker J., Westhovens R., Hochberg M., et al. The long-term safety of abatacept in the treatment of rheumatoid arthritis: integrated analyses from the abatacept clinical trial program. Ann Rheum Dis 2010, 69(Suppl 3):377.
15. Smitten A., Westhovens R., Hochberg M., et al. Serious infections and malignancies during long-term exposure to abatacept. Ann Rheum Dis 2010, 69(Suppl 3):541.
16. Zhang X.-L., Peng J., Sun J.-Z., et al. Modulation of immune response with cytotoxic T-lymphocyte associated antigen 4 immunoglobulin-induced anergic T cells in chronic idiopathic thrombocytopenic purpura. J Thromb Haemost 2008, 6:158-165.
17. Naz S.M., Symmons D.P. Mortality in established rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007, 21:871-883.
18. Strangfeld A., Listing J. Infection and musculoskeletal conditions: bacterial and opportunistic infections during anti-TNF therapy. Best Pract Res Clin Rheumatol 2006, 20:1181-1195.
19. Michaud K., Wolfe F. Comorbidities in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007, 21:885-906.
20. Summary of Product Characteristics for abatacept.(july 2010).
21. Sibilia J., Westhovens R. Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis. Clin Exp Rheumatol 2007, 25(Suppl 46):S46-S56.
22. Prevention et prise en charge des tuberculoses survenant sous anti-TNF-alpha. AFSSAPS Juillet 2005. http://www.agmed.sante.gouv.fr/htm/10/tnf/reco.pdf.
23. Mahajan T.D., Hooker R., Maher L., et al. Abatacept therapy for rheumatoid arthritis in the setting of hepatitis C infection. J Clin Rheumatol 2010, 16:332-334.
24. Furst D.E., Breedveld F.C., Kalden J.R., et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases. Ann Rheum Dis 2007, 66(Suppl 3):iii2-iii22.
25. Mise au point: Antibiotherapie par voie generale dans les infections respiratoires basses de l'adulte - pneumonie aigue communautaire - exacerbations de Bronchopneumopathie Chronique Obstructive. AFSSAPS, Juillet 2010.
26. Khraishi M., Russell A., Olszynski W. Safety profile of abatacept in rheumatoid arthritis: a review. Clin Ther 2010, 11:1855-1870.
27. Schiff M. Abatacept treatment for rheumatoid arthritis. Rheumatology (Oxford) 2011, 50:437-449.
28. Westhovens R., Kremer J., Moreland L.W., et al. Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study." J Rheumatol 2009, 36(4):736-742.
29. Simon T.A., Askling J., Lacaille D., et al. Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment. Arthritis Res Ther 2010, 12:R67.
30. Furst D.E. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 2010, 39:327-346.
31. Schiff M., Keiserman M., Codding C., et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multicentre, randomized, double-blind, placebo controlled study in patients with RA and in inadequate response to methotrexate. Ann Rheum Dis 2008, 67:1096-1103.
32. Weinblatt M., Combe B., Covucci A., et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and non biologic disease-modifying anti rheumatic drugs: a one year randomized, placebo controlled study. Arthritis Rheum 2006, 54:2807-2816.
33. Weinblatt M., Schiff M., Goldman A., et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomized clinical trial. Ann Rheum Dis 2007, 66:228-234.
34. Singh J.A., Wells G.A., Christensen R., et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011, 2:CD008794. Feb 16.
35. Salliot C., Dougados M., Gossec L. Risk of serious infections during rituximab, abatacept and anakinra therapies for rheumatoid arthritis: meta-analyses of randomized placebo-controlled trials. Ann Rheum Dis 2009, 68:25-32.
36. Hunter C.A., Reiner S.L. Cytokines and T cells in host defense. Curr Opin Immunol 2000, 12:413-418.
37. Bertram E.M., Dawicki W., Watts T.H. Role of T cell costimulation in antiviral immunity. Semin Immunol 2004, 16:185-196.
38. Hunter C.A., Lieberman L.A., Mason N., et al. Costimulation in resistance to infection and development of immune pathology: lessons from toxoplasma. Immunol Res 2003, 27:331-340.
39. Rose C.M., Kimzey S.L., Green J.M. The host response of CD28-deficient mice to pneumocystis infection. Microb Pathog 2006, 40:23-28.
40. Marks E., Verolin M., Stensson A., et al. Differential CD28 and inducible costimulatory molecule signalling requirements for protective CD4+ T-cell-mediated immunity against genital tract Chlamydia trachomatis infection. Infect Immun 2007, 75:4638-4647.
41. Bigbee C.L., Gonchoroff D.G., Vratsanos G., et al. Abatacept treatment does not exacerbate chronic mycobacterium tuberculosis infection in mice. Arthritis Rheum 2007, 56:2557-2565.
42. Haggerty H.G., Nadler S.G., Simon T.A., et al. Utilization of host resistance models (HRMs) in the prediction of human safety of abatacept (ABA): a translational approach. Arthritis Rheum 2007, 56(Suppl):S701.
43. Smitten A., Simon T., Qi K., et al. Malignancies in the abatacept RA clinical development program: an updated epidemiological assessment with >10,000 person-years of exposure. Arthritis Rheum 2008, 58(Suppl 9):S787.
44. Ruperto N., Lowell D.J., Quartier P., et al. Long-Term Safety and Efficacy of Abatacept in Children with Juvenile Idiopathic Arthritis. Arthritis Rheum 2010, 62:1792-1802.
45. Schiff M., Poncet C., Le Bars M. Efficacy and safety of abatacept therapy for rheumatoid arthritis in routine clinical practice. Int J Clin Rheumatol 2010, 5:581-591.
46. Mariette X., Gottenberg J.E., Ravaud P., Combe B. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Rheumatology (Oxford) 2011, 50:222-229.
47. Kremer J.M., Genant H.K., Moreland L.W., et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006, 144:865-876.
48. Karie S, Launay-Vacher V, Deray G. Guide de prescription des medicaments chez le patient insuffisant renal (GPR Immunosuppresseurs). 2006.
49. Weclawiak H., Kamar N., Ould-Mohamed A., et al. Biological agents in kidney transplantation: belatacept is entering the field. Expert Opin Biol Ther 2010, 10:1501-1508.
50. Vincenti F., Blancho G., Durrbach A., et al. Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol 2010, 21:1587-1596.
51. Michel M., Habibi A., Godeau B., et al. Characteristics and outcome of connective tissue diseases in patients with sickle-cell disease: report of 30 cases. Semin Arthritis Rheum 2008, 38:228-240.
52. Nistala K., Murray K.J. Co-existent sickle cell disease and juvenile rheumatoid arthritis. Two cases with delayed diagnosis and severe destructive arthropathy. J Rheumatol 2001, 28:2125-2128.
53. Musa B.O., Onyemelukwe G.C., Hambolu J.O., et al. Pattern of serum cytokine expression and T-cell subsets in sickle cell disease patients in vaso-occlusive crisis. Clin Vaccine Immunol 2010, 17:602-608.
54. Wallace K.L., Marshall M.A., Ramos S.I., et al. NKT cells mediate pulmonary inflammation and dysfunction in murine sickle cell disease through production of IFN-gamma and CXCR3 chemokines. Blood 2009, 114:667-676.
55. Caporali R., Bugatti S., Rossi S., et al. Rheumatoid arthritis in beta-thalassemic trait: clinical, serologic and immunogenetic profile. Joint Bone Spine 2004, 71:117-120.
56. Giakoumi X., Tsironi M., Floudas C., et al. Rheumatoid arthritis in thalassemia intermedia: coincidence or association?. Isr Med Assoc J 2005, 7:667-669.
57. Adams A.B., Durham M.M., Kean L., et al. Costimulation blockade, busulfan, and bone marrow promote titratable macrochimerism, induce transplantation tolerance, and correct genetic hemoglobinopathies with minimal myelosuppression. J Immunol 2001, 167:1103-1111.
58. Kean L.S., Durham M.M., Adams A.B., et al. A cure for murine sickle cell disease through stable mixed chimerism and tolerance induction after nonmyeloablative conditioning and major histocompatibility complex-mismatched bone marrow transplantation. Blood 2002, 99:1840-1849.
59. Kruetzmann S., Rosado M.M., Weber H., et al. Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen. J Exp Med 2003, 197:939-945.
60. Di Carlo I., Primo S., Pulvirenti E., et al. Should all splenectomised patients be vaccinated to avoid OPSI? Revisiting an old concept: an Italian retrospective monocentric study. Hepatogastroenterology 2008, 55:308-310.
61. Antibioprophylaxie en chirurgie et medecine interventionnelle (Patients adultes). Actualisation 2010, Societe Francaise d'anesthesie et de Reanimation.
62. Legrand A., Bignon A., Borel M., et al. Perioperative management of asplenic patients. Ann Fr Anesth Reanim 2005, 24:807-813.
63. Jones P., Leder K., Woolley I., et al. Postsplenectomy infection - strategies for prevention in general practice. Aust Fam Physician 2010, 39:383-386.
64. LeMessurier K., Hacker H., Tuomanen E., et al. Inhibition of T cells provides protection against early invasive pneumococcal disease. Infect Immun 2010, 78:5287-5294.
65. Kremer J.M., Genant H.K., Moreland L.W., et al. Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum 2008, 58:953-963.
66. Goeb V., Buch M.H., Vital E.M., et al. Costimulation blockade in rheumatic diseases: where we are?. Curr Opin Rheumatol 2009, 21:244-250.
67. Genant H.K., Peferty C.G., Westhovens R., et al. Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann Rheum Dis 2008, 67:1084-1089.
68. Moreland L.W., Alten R., Van den Bosch F., et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dosefinding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 2002, 46:1470-1479.
69. Schiff M., Pritchard C., Huffstutter J.E., et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis 2009, 68:1708-1714.
70. Record J.L., Beukelman T., Cron R.Q. Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series. J Rheumatol 2011, 38:180-181.
71. Mishra R., Singh V., Pritchard C.H. Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis. Rheumatol Int 2011, 31:481-484.
72. Gottenberg J.E., Flipo R.M., Cantagrel A., et al. Switching from rituximab to abatacept: tolerance data of 179 patients prospectively followed up in the "Orencia and Rheumatoid Arthritis" (ORA) registry. EULAR 2010, Abstr. FRI0210.
73. Axmann R., Herman S., Zaiss M., et al. CTLA-4 directly inhibits osteoclast formation. Ann Rheum Dis 2008, 67:1603-1609.
74. Pham T., Fautrel B., Gottenberg J.E., et al. Rituximab (Mabthera) therapy and safety management. Clinical tool guide elaborated by the Rheumatic Diseases and inflammation Group (Club Rhumatismes et Inflammation, CRI), of the French Society of Rheumatology (Societe Francaise de Rhumatologie, SFR). Joint Bone Spine 2008, 75(Suppl 1):S1-S99.
75. Gemmell E., McHugh G.B., Grieco D.A., Seymour G.J. Costimulatory molecules in human periodontal disease tissues. J Periodont Res 2001, 36:92-100.
76. Tong D.C., Rothwell B.R. Antibiotic prophylaxis in dentistry: a review and practice recommendations. J Am Dent Assoc 2000, 131:366-374.
77. Tsai A.F., Kaufman K.A., Walker M.A., et al. Transmission disequilibrium of maternally-inherited CTLA-4 microsatellite alleles in idiopathic recurrent miscarriage. J Reprod Immunol 1998, 40:147-157.
78. Kaufman K.A., Bowen J.A., Tsai A.F., et al. The CTLA-4 gene is expressed in placental fibroblasts. Mol Hum Reprod 1999, 5:84-87.
79. Von Rango U. Fetal tolerance in human pregnancy - A crucial balance between acceptance and limitation of trophoblast invasion. Immunol Lett 2008, 115:21-32.
80. Jin L.P., Zhou Y.H., Wang M.Y., et al. Blockade of CD80 and CD86 at the time of implantation inhibits maternal rejection to the allogeneic fetus in abortion-prone matings. J Reprod Immunol 2005, 65:133-146.
81. Wang X., Lin Q., Ma Z., et al. Association of the A/G polymorphism at position 49 in exon 1 of CTLA-4 with the susceptibility to unexplained recurrent spontaneous abortion in the Chinese population. Am J Reprod Immunol 2005, 53:100-105.
82. FDA Pharmacological review. http://www.fda.gov/cder/foi/nda/2005/125118_S0000_PharmR.pdf.
83. Health Canada, Summary basis of decision Abatacept. http://www.hcsc.gc.ca/dhpmps/alt_formats/hpfbdgpsa/pdf/prodpharma/sbd_smd_2007_orencia_098531_e.pdf.
84. Oei H.B., Hooker R.S., Cipher D.J., Reimold A. High rates of stopping or switching biological medications in veterans with rheumatoid arthritis. Clin Exp Rheumatol 2009, 27:926-934.
85. Tran S., Hooker R.S., Cipher D.J., Reimold A. Patterns of biologic agent use in older males with inflammatory diseases: an institution-focused, observational post-marketing study. Drugs Aging 2009, 26:605-615.
86. Elkayam O., Caspi D., Reitblatt T., et al. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with Rheumatoid Arthritis and Ankylosing Spondylitis. Semin Arthritis Rheum 2004, 33:283-288.
87. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009, 50:227-242. European Association for the Study of the Liver.
88. Tay L., Leon F., Vratsanos G., et al. Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects. Arthritis Res Ther 2007, 9:R38.
89. Wu Z.Q., Shen Y., Khan A.Q., et al. The mechanism underlying T cell help for induction of an antigen-specific in vivo humoral immune response to intact Streptococcus pneumoniae is dependent on the type of antigen. J Immunol 2002, 168:5551-5557.
90. Jeurissen A., Wuyts G., Kasran A., et al. The human antibody reponse to pneumococcal capsular polysaccharides is dependent on the CD40-CD40 ligand interaction. Eur J Immunol 2004, 34:850-858.
91. Ndejembi M., Patke D., Bingaman A. CTLA-4Ig inhibits IL-2 production and in vivo expansion of antigen- stimulated memory CD4 T cells. Clin Immunol 2005, 115:S219-S220.
92. Schaeverbeke T., Vittecoq O., Dougados M., et al. Etude de la reponse immunitaire au vaccin antigrippal chez les patients ayant une polyarthrite rhumatoide et traites par abatacept. Rev Rhum 2007, 74:1066-1067. Abstract in French.
93. Kuemmerle-Deschner J.B., Benseler S.M. Abatacept in difficult-to-treat juvenile idiopathic arthritis. Biologics 2008, 2:865-874.
94. Goldzweig O., Hashkes P.J. Abatacept in the treatment of polyarticular JIA: development, clinical utility, and place in therapy. Drug Des Devel Ther 2011, 5:61-70.
95. Ruperto N., Lovell D.J., Quartier P., et al. Abatacept in children with JIA: A randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008, 372:383-391.
96. Ruperto N., Lovell D.J., Li T., et al. Abatacept improves health-related quality of life, pain, sleep quality and daily participation in subjects with JIA. Arthritis Care Res (Hoboken) 2010, 62:1542-1551.
97. Saurenmann R.K., Levin A.V., Feldman B.M., et al. Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term followup study. Arthritis Rheum 2007, 56:647-657.
98. Shao H., Woon M.D., Nakamura S., et al. Requirement of B7-mediated costimulation in the induction of experimental autoimmune anterior uveitis. Invest Ophthalmol Vis Sci 2001, 42:2016-2021.
99. Zulian F., Balzarin M., Falcini F., et al. Abatacept for severe anti-tumor necrosis alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res (Hoboken) 2010, 62:821-825.
100. Angeles-Han S., Flynn T., Lehman T. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis: a case report. J Rheumatol 2008, 35:1897-1898.
101. Kenawy N., Cleary G., Mewar D., et al. Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritisassociated uveitis. Graefes Arch Clin Exp Ophthalmol 2011, 249:297-300.
102. Elhai M., Job-Deslandre C., Kahan A. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis: two new cases. Comment on the article by Zulian et al. Arthritis Care Res (Hoboken) 2011, 63:307-310.
103. Ungar W.J., Costa V., Hancock-Howard R., et al. Cost-effectiveness of biologics in polyarticular-course juvenile idiopathic arthritis patients unresponsive to disease-modifying antirheumatic drugs. Arthritis Care Res (Hoboken) 2011, 63:111-119.
104. Giannini E.H., Ruperto N., Ravelli A., et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997, 40:1202-1209.
105. Olivieri I., D'Angelo S., Mennillo G.A., et al. Abatacept in spondyloarthritis refractory to tumour necrosis factor alpha inhibition. Ann Rheum Dis 2009, 68:151-152.
106. Berber B., Schedel J., Guenaydin I., et al. Abatacept for therapy of spondyloarthritis due to therapy failure or contraindications of TNF-alpha antagonists. Ann Rheum Dis 2009, 68:623.
107. Compaore C., D'Agostino M.A., Belmiloud S., et al. Traitement de la spondylarthrite (SpA) axiale refractaire aux anti-TNFalpha par CTLA4-Ig (abatacept); resultats d'une etude ouverte pilote. Revue du Rhumatisme 2009, 76:1132.
108. Song I.H., Heldmann F., Rudwaleit M., et al. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis 2011, 70:1108-1110.
109. Lekpa F.K., Farrenq V., Canoui-Poitrine F., et al. Lack of efficacy of abatacept in axial spondylarthropathies refractory to tumornecrosis-factor inhibition. Joint Bone Spine 2011, Apr 14 [Epub ahead of print].
110. Rodrigues C.E., Vieira F.J., Callado M.R., et al. Use of the abatacept in a patient with psoriatic arthritis. Rev Bras Reumatol 2010, 50:340-345.
111. Canete J.D., Celis R., Hernandez V., et al. Synovial immunopathological changes associated with successful abatacept therapy in a case of severe refractory psoriatic arthritis. Ann Rheum Dis 2010, 69:935-936.
112. Vieira F.J., Callado M.R., Vieira W.P. Abatacept as an option therapy in difficult to treat psoriatic arthritis. Rheumatol Int 2010, 30:849-850.
113. Mease P., Genovese M.C., Gladstein G., et al. Abatacept in the treatment of patients with psoriatic arthritis: Results of a double blind, randomized, placebo-controlled phase 2 trial. Arthritis Rheum 2010, [Epub ahead of print] PubMed PMID: 21128258.
114. Crispin J.C., Kyttaris V.C., Terhorst C., et al. T-cells as therapeutic targets in SLE. Nat Rev Rheumatol 2010, 6:317-325.
115. Rahman A., Isenberg D.A. Systemic lupus erythematosus. N Engl J Med 2008, 358:929-939.
116. Spronk P.E., Horst G., van der Gut R.T., et al. Anti-dsDNA production coincides with concurrent B and T cell activation during development of active disease in systemic lupus erythematosus (SLE). Clin Exp Immunol 1996, 104:446-453.
117. Daikh D.I., Wofsy D. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol 2001, 166:2913-2916.
118. Oracki S.A., Tsantikos E., Quillici C., et al. CTLA4Ig alters the course of autoimmune disease development in Lyn-/- mice. J Immunol 2010, 184:757-763.
119. Merrill J.T., Burgos-Vargas R., Westhovens R., et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010, 62:3077-3087.
120. Bertsias G., Loannidis J.P., Boletis J., et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008, 67:195-205.
121. Lupus erythemateux systemique: Protocole National de Diagnostic et de Soins. Janvier 2010. http://www.hassante.fr/portail/upload/docs/application/pdf/2010-03/ald_21_pnds_lupus_web.pdf.
122. Genovese M.C., Covarrubias A., Leon G., et al. Subcutaneous abatacept versus intravenous abatacept. A Phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum 2011, 63:2854-2864.
123. Murthy B, Gao L, Vakkalagadda B, et al. Clinical pharmacokinetics of subcutaneous abatacept in the presence or absence of an Intravenous loading dose in patients with rheumatoid arthritis. EULAR 2011-3594.
124. Genovese M.C., Cobos A.C., Leon G., et al. Subcutaneous Abatacept Versus Intravenous ABA in Patients with Rheumatoid Arthritis: Long-Term Data From the ACQUIRE (Abatacept Comparison of Sub[QU]cutaneous versus Intravenous in Inadequate Responders to MethotrexatE) Trial. ACR 2011, Abstr 19454.
125. Keystone E., Kremer J., Russell A., et al. Switching patients with rheumatoid arthritis from intravenous to subcutaneous abatacept is well tolerated and sustains previously established efficacy. EULAR 2011, Abstr 1536.
126. Kaine J., Gladstein G., Strusberg I., et al. Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (Phase IIIb ALLOW study). Ann Rheum Dis 2011, 71:38-44.
127. Mandell L.A., Wunderink R.G., Anzueto A., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007, 44(Suppl 2):S27-S72.
128. Levy M.L., Le Jeune I., Woodhead M.A., et al. Primary care summary of the British Thoracic Society Guidelines for the management of community acquired pneumonia in adults: 2009 update. Endorsed by the Royal College of General Practitioners and the Primary Care Respiratory Society UK. Prim Care Respir J 2010, 19:21-27.